« Return to News | Drug Sponsors

Eli Lilly 's new anti-psychotic offers no weight gain

Wednesday, April 27, 2011 12:49 PM

The schizophrenia drug Zyprexa was one of Eli Lilly's biggest success stories; however, the company has also paid big settlements regarding claims that it hid data about a burdensome weight-gain side effect. As a result, Lilly has begun late-stage trials for a next-generation schizophrenia drug that offers treatment without weight gain, according to FierceBiotech.

For now, the drug is called LY2140023 and will hopefully complete all trial phases by 2013, potentially seeing FDA approval in 2014.

Fierce notes that the treatment works differently than atypical antipsychotics such as Zyprexa. Instead of blocking dopamine, the new treatment stimulates metabotropic glutamate receptors, or mGlu. In 2007, Lilly produced mid-stage data indicating that the drug successfully treated schizophrenia, without the weight gain. Yet, in 2009, the company also had to discount data that failed to demonstrate the drug's superiority over a placebo, faulting the study design.

Lilly remains hopeful for success from phase III of the design, but the company is also searching to find a possible genetic profile more likely to respond positively.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.